iTonic Holdings Ltd
ITOCNasdaq
$0.28
↓ -6.1%Jul 17 close · end-of-day
Price
1Y↓ -98.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.5M
Enterprise Value
$1.6M
P/E
—
P/S
8.7
P/B
0.7
EV/EBITDA
—
PEG
—
FCF Yield
-71.5%
Dividend Yield
—
Revenue (TTM)
$523,031.00
Net Income (TTM)
-$5.1M
Free Cash Flow (TTM)
-$3.2M
Gross Margin
62.6%
Operating Margin
-991.7%
Net Margin
—
ROE
—
ROIC
-128.2%
Debt / Equity
—
Net Cash
$2.9M
Return 1Y
-98.7%
Company profile
iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients. The company was formerly known as Pheton Holdings Ltd and changed its name to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. was founded in 1998 and is headquartered in Beijing, China. iTonic Holdings Ltd. operates as a subsidiary of ZJW (BVI) LTD.
- CEO
- Jianfei Zhang
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Website
- www.ftzy.com.cn/
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $679,777.00 | $628,591.00 | $448,196.00 | $523,031.00 |
| Gross profit | $558,150.00 | $470,828.00 | $381,155.00 | $327,351.00 |
| Operating income | $27,521.00 | -$306,680.00 | -$770,266.00 | -$5.2M |
| Net income | $83,980.00 | -$241,217.00 | -$660,588.00 | -$5.1M |
| Diluted EPS | $0.01 | -$0.02 | -$0.05 | -$0.32 |
| Operating cash flow | -$116,152.00 | -$63,636.00 | -$775,000.00 | -$3.2M |
| Free cash flow | — | — | -$775,861.00 | -$3.2M |
| Gross margin | 82.1% | 74.9% | 85.0% | 62.6% |
| Operating margin | 4.0% | -48.8% | -171.9% | -991.7% |
| Net margin | 12.4% | -38.4% | -147.4% | -974.7% |
No quarterly data.
Company news
Jan 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.